Previous 10 | Next 10 |
HOUSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced its participation at two upcoming investor conferences during the month of September. ...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its Chief Executive Officer, David Arthur, will present during the 2020 ...
Salarius Pharmaceuticals, Inc. (SLRX) Q2 2020 Earnings Conference Call August 12, 2020, 16:30 ET Company Participants David Arthur - CEO, President & Director Mark Rosenblum - EVP, Finance & CFO Nadeem Mirza - SVP, Clinical Development Daniela Santiesteban - Director, R...
Salarius Pharmaceuticals (NASDAQ: SLRX ) : Q2 GAAP EPS of -$0.13 beats by $0.04 . More news on: Salarius Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company Closes $6.2M Public Offering and Expands Clinical Program to Include Ewing-Related Sarcomas Conference Call and Live Audio Webcast Scheduled for Today, August 12, 2020, at 4:30 p.m. ET HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: S...
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the Company will host a conference call and live audio webcast on Wednesday, Aug...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead inve...
HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. . (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the u...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...